Xaluprine 20 mg/ml oral suspension * Pharmacy Only: Prescription
Company:
Nova Laboratories Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 27 June 2022
File name
62b997aba1ecf.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to restricted prescription (C)
Updated on 27 June 2022
File name
62b9978f3866c.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 27 June 2022
File name
62b977863396a.pdf
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 27 June 2022
File name
62b977624f5d7.pdf
Reasons for updating
- Change to section 6 - date of revision
Updated on 24 June 2022
File name
62b56f70b99ab.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to restricted prescription (C)
Updated on 24 June 2022
File name
62b56f4bb094e.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 23 June 2022
File name
62b475c33b1d1.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to restricted prescription (C)
Updated on 23 June 2022
File name
62b4733b681ea.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 13 January 2022
File name
SPC_1642089595.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category:Product subject to restricted prescription (C)
Updated on 12 March 2021
File name
PIL_1615566098.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 07 February 2021
File name
PIL_1612695535.pdf
Reasons for updating
- Change to section 6 - manufacturer
Free text change information supplied by the pharmaceutical company
Addition of Pronav Clinical Ltd. as manufacturer.
Updated on 08 June 2020
File name
Summary of Product Characteristics_1591610122.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to restricted prescription (C)
Updated on 08 June 2020
File name
Package Leaflet_1591609943.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - excipient warnings
- Change to section 3 - how to take/use
Updated on 17 December 2019
File name
Summary of product characteristics_1576596100.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 17 December 2019
File name
Package leaflet_1576596073.pdf
Reasons for updating
- New PIL for new product